Warburg Pincus plans to spend more than US$7 billion to acquire US specialty pharmaceutical companies and join hands with the UAE sovereign fund to deepen the layout of the medical industry
According to people familiar with the matter, Warburg Pincus, the world's top private equity investment institution, is in in-depth negotiations with Pantherx Rare, a U.S. specialty pharmaceutical and rare disease drug service provider, and plans to acquire it at a transaction consideration of more than US$7 billion (including debt). This move marks that in the context of global private equity capital facing stagnant pressure to exit investment portfolios, core medical and health assets have once again become the focus of competition among large international consortiums. People familiar with the matter pointed out that Warburg Pincus plans to join hands with its strategic partner, the UAE sovereign wealth fund Abu Dhabi Investment Authority ( A) Co-financing. At present, the specific transaction terms are close to being finalized. Although the final time point is still subject to fine-tuning, it is expected that the huge acquisition will be officially implemented in the short term. Pantherx Rare, headquartered in Pittsburgh, USA, is a specialty pharmacy and personalized care service provider focusing on rare diseases and orphan drugs (Orphan Diseases). The company was previously owned by U.S. health insurance giant Centene Corp. hold. In 2022, in order to focus on its core medical insurance business, Centene will divest it and transfer it to a private equity investment consortium composed of General Atlantic, Nautic Partners and Vistria Group. Industry analysts believe that the current global private equity investment (PE) industry generally faces structural challenges such as blocked exit channels and a backlog of unrealized assets. Therefore, high-quality medical assets with stable cash flow are becoming a "catalyst" to boost the activity of M&A transactions. As an industry giant with assets under management exceeding US$10.5 billion, Warburg Pincus has continued to increase capital investment in life sciences and clinical research in recent years. It already owns important sectors such as START Cancer Research Center and sterile injection manufacturer Simtra BioPharma Solutions. In addition, this acquisition is also the re-union of Warburg Pincus and the Abu Dhabi Investment Authority in the field of cross-border joint investment. Previously, both parties jointly injected capital into India's IDFC FIRST Bank. With the advancement of this transaction of over US$7 billion, the capital integration process in the global rare disease pharmaceutical services field is expected to accelerate significantly.